Enliven Therapeutics, Inc. (NASDAQ:ELVN) Sees Significant Decrease in Short Interest

Enliven Therapeutics, Inc. (NASDAQ:ELVN) was the target of a significant drop in short interest in January. As of January 30th, there was short interest totaling 7,870,182 shares, a drop of 14.1% from the January 15th total of 9,166,736 shares. Approximately 17.9% of the company’s stock are sold short. Based on an average trading volume of 997,280 shares, the days-to-cover ratio is currently 7.9 days. Based on an average trading volume of 997,280 shares, the days-to-cover ratio is currently 7.9 days. Approximately 17.9% of the company’s stock are sold short.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $29.04, for a total value of $145,200.00. Following the completion of the transaction, the insider directly owned 740,188 shares of the company’s stock, valued at $21,495,059.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $26.75, for a total transaction of $32,902.50. Following the completion of the sale, the director owned 23,877 shares of the company’s stock, valued at $638,709.75. This trade represents a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 232,613 shares of company stock worth $6,113,287. Insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP lifted its holdings in Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after acquiring an additional 17,809 shares during the period. Vestal Point Capital LP increased its holdings in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares in the last quarter. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after purchasing an additional 418,673 shares during the period. Vanguard Group Inc. boosted its holdings in Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares in the last quarter. Finally, State Street Corp boosted its holdings in Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after buying an additional 87,725 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $26.37 on Thursday. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.22. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -14.33 and a beta of 0.34. The firm’s fifty day moving average is $22.51 and its two-hundred day moving average is $21.07.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.